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Introduction
Inborn Errors of Metabolism (IEM) are a class of genetic diseases involving genes which code 
for enzymes or transporters in metabolism. Patients with IEM produce defective enzymes or 
transporters from defective genes. This hinders metabolic pathways which convert substrates into 
desirable products, leading to (1) failure in synthesizing essential biochemical compounds; and/or 
(2) accumulation of substances that are toxic or could interfere with normal physiological function 
and may contribute to morbidity and mortality.
Individual cases of IEM are rare but collectively, IEM diseases are prevalent [1]. The cumulative 
incidence rate varies among countries from 1 in 784 live births in United Kingdom [1] to 1 in 
9300 in Japan [2]. Ethnicity-related discrepancies by country is in part due to variation of IEM 
panels being used for screening, impeding direct comparison [3].With a greater understanding of 
the pathophysiology and the availability of emerging biochemical and molecular diagnostic tools, 
more types of IEM are being identified [4].
Depending on the pathogenesis and the metabolic pathway affected, classical IEM is grossly 
classified into different groups: amino acidemias, organic acidemias (OA), and fatty acid oxidation 
defects. Of the various types of IEM diseases, OA most frequently occur among severely ill children 
[5].
Although clinical presentations of OA involve multiple body systems, OA predominately affects 
the central nervous system. If OA is not treated, patients may develop irreversible brain damage, 
leading to mental retardation. Long-term management requires a low-protein-high-energy diet 
with amino acid supplements which are free from the problematic precursor amino acids. Response 
to treatment for OA is generally good, particularly among neonates before onset of symptoms [4,6]. 
As supported in multiple studies [7-9], early identification by screening and timely intervention 
significantly improves clinical outcomes.
In recent years, the use of tandem mass spectrometry (TMS) allows screening of multiple 
diseases from one test. Chace, et al. [10] demonstrated the use of TMS in IEM screening using dried 
blood spots (DBS). Confirmatory testing can be performed with analysis of plasma amino acids, 
plasma acylcarnitines and urine organic acids; and genetic diagnosis by DNA sequencing [3].
This screening strategy has multiple advantages. Firstly, TMS has high sensitivity (99%) and 
specificity (99.995%) for most IEM diseases [11-13]. Secondly, only a 0.3 ml whole blood sample 
is needed for the DBS card; this amount is comparatively small and attainable from neonates [12]. 
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Abstract
Aim: This study assesses the cost-effectiveness of population-wide organic acidemias newborn screening 
in Hong Kong from the public healthcare provider’s perspective.
Methods: A decision tree was established to model the effect of screening birth cohort in Hong Kong in 2009 
compared with no screening. Life-time costs and benefits were considered. Screening test performance, outcome 
probabilities and costs were obtained from the international literature and local sources. A yearly discount rate of 
5% was applied to costs and benefits. Incremental Cost-Effectiveness Ratio (ICER) was calculated per life year 
gained (overall) and per life year gained without mental retardation.
Results: The ICER per life year gained for all newborns is -HK$1,300,177 and the ICER per life year gained 
without mental retardation is -HK$983,333, for screening as compared with no screening strategy. 
Conclusion: Newborn screening for organic acidemias is shown to be highly cost-effective for avoidable 
mortality and mental retardation development.
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In addition, it has the potential of accommodating high-throughput 
environment for newborn screening, as it requires only 3 minutes to 
screen 30 diseases [11]. Furthermore, the cost of test reagents is low. 
Despite relatively high installation and setup costs; the incremental 
marginal cost was calculated to be about $10 USD per birth screen 
[12].
Newborn screening has been shown to be cost-effective in various 
studies [16]. These studies are specific to the local situation, in terms 
of disease of interest, disease epidemiology, healthcare cost, study 
perspective, and treatment and management models. These studies 
used various methodological approaches and implementation 
strategies, reported on a unique panel of diseases and disease 
incidence. Service delivery costs were obtained from the healthcare 
provider. Hence, newborn screening cost-effectiveness analyses may 
not be transferrable from one country or locality to another. 
In Hong Kong, incidence for classical IEM was estimated to be 1 
in 4,122 [17]. Universal newborn screening provided by Department 
of Health for genetic defects has been limited to G6PD deficiency and 
congenital hypothyroidism. The screening strategy in China (using 
TMS-based platform) has shown potential for adoption in Hong Kong 
and may guide development of higher neonatal screening standards. 
Lee, et al. [18] found that TMS-based expanded IEM screening to be 
cost effective for hyperphenylalaninemia in Hong Kong. Inclusion 
of OA in newborn screening requires economic justification. The 
cost-effectiveness of such programme in Hong Kong has yet to be 
addressed in scientific research papers. Hence, this study assessed the 
cost-effectiveness of additionally including OA to an existing TMS-
based newborn hyperphenylalaninemia screening platform.
Materials and Methods
Perspective and setting
This study takes the perspective of a Hong Kong public healthcare 
provider. Only direct costs related to the screening programme 
and utilization of health care services: cost of confirmation test, 
consultation, and management costs are considered in this model. 
As TMS platform is already in place for hyperphenylalaninemia 
screening, there is no installation and setup cost. Reagent cost for 
screening test is negligible for additionally include OA, due to the 
nature of the TMS-screening strategy (one test for screening multiple 
diseases). The monetary values in 2009 are used and a discount rate of 
5% per year is applied for both costs and benefits [19].
Cases Based on a Local Inborn Errors of Metabolism Study
This study is based on a study previously conducted by Lee, et 
al. [17] to estimate the incidence and disease spectrum of classical 
IEM, including OA. Five years of laboratory records (2005 to 2009) 
were retrieved to identify IEM cases from three regional chemical 
pathology laboratories in Hospital Authority (HA) [17]. These cases 
were reviewed and confirmed by genetic analysis. Eventually, 43 
IEM cases, of which 5 cases were classified as OA, met the inclusion 
criteria. 
Incidence for classical IEM in Hong Kong was then estimated to 
be 1 in 4,122 [17]. The identified OA patients are followed up in this 
study. With the approval from Kowloon West Cluster Research Ethics 
Committee of the HA, and the Institutional Review Board, service 
utilization for these patients was retrospectively retrieved from the 
Clinical Management System. Five-year records of hospitalization, 
consultation, and imaging service were retrieved for utilization review 
and costing. Costs were based on “charges for non-eligible persons 
(NEP)” [20] of HA; average annual cost was subsequently calculated.
Decision tree model
A decision tree model was established to compare TMS-based 
screening versus no-screening strategy in the cohort of newborn 
babies in 2009. The model considered possible pathways and 
associated probabilities and outcomes (Figure 1).
For the screening group: for test-positive subjects, confirmation 
tests and genetic analysis were included to distinguish between 
true positive and false positive. Sensitivity and specificity of the 
confirmation tests were assumed to be 100% each. True positives 
were expected to be picked up for prompt treatment. It was assumed 
that a specialist out-patient visit was required quarterly for follow-up 
and prescription.
Figure 1: Decision Tree of the Organic Acidemia screening.
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Screening test-negative subjects were either healthy (true 
negative) or missed OA (false negative). The latter would be identified 
when clinical symptoms arise.
For no screening group: OA patients were identified only when 
clinical symptoms arise. These types of patients, like missed OA, were 
regarded as having delayed treatment. Age-specific event probabilities 
were applied to these subjects to calculate the total number of life 
years lost and the total number of life years with mental retardation 
up to life expectancy. Life-time management cost was calculated as 
summation of average annual management cost up to life expectancy.
The cohort was assumed to be homogenous in terms of OA risk, 
complication rate and response to treatment, and was expected to 
undergo either population-wide TMS OA screening strategy or no 
screening. The compliance rate was assumed to be 100% with no 
drop-outs.
Given the severe nature of complications [10], the treatment 
compliance rate was assumed to be 100%. Medication use for any 
detected cases was assumed to be same across cases. Despite good 
response to treatment for OA among neonates [4,6], published 
data on treatment effectiveness is limited. Therefore, treatment 
effectiveness for avoiding mortality and/or mental retardation in 
early detected cases is both assumed to be 100%.
Estimates were obtained from published research on MEDLINE/
PubMed, and from local sources. Rare diseases like OA are usually 
studied as case series and observational studies. Data quality was 
ensured by two criteria (1) applicability with the Hong Kong 
context: data from Hong Kong is preferred to China, then Asia and 
international; (2) reliability of data: sample size and length of the 
study.
Cost-effectiveness analysis
The primary outcome is the incremental cost-effectiveness ratio 
(ICER): ICER per life year gain (overall), and ICER per life year gain 
without mental retardation. It is calculated by the formula: [ICER = 
△C/△E], where, △C = the difference in total cost between screening 
and no screening for OA; and, △E = the difference in effectiveness 
[(i) cost per life-year gained (overall); (ii) cost-per life year gained 
without mental retardation] 
The ICER threshold is set at per capita gross domestic product 
(GDP) of 2009, which is HK$233,239 per life-year gained [22].The 
World Health Organization [19] recommends that, a programme is 
(1) highly cost-effective if ICER is less than GDP per capita; (2) cost-
effective if ICER falls between one and three times GDP per capita; 
or (3) not cost-effective if ICER is greater than three times GDP per 
capita.
Results
Use of estimates
The major estimates for calculation of life years and costs in 
different decision tree pathways, extracted from published search on 
MEDLINE/PubMed and from local sources, are summarized in Table 1.
Parameter Estimates References
Discount Rate 5% [19]
Birth Cohort 2009
- Cohort size
- Life Expectancy
82,100
79.8 years [21]
Disease Burden of Organic Acidemias
- Incidence 
- Mortality rate
Early detection
Late detection:
- Year 0 to Year 1
- Year 1 to Year 2
- Year 2 to Year 5
- Year 5 to Year 15
- Year 15 to Year 80
- Probability of developing of mental retardation
Early detection
Late detection
- Year 1 to Year 2
- Year 2 to Year 5
- Year 5 to Year 15
- Year 15 to Year 80
1 in 35,534
0%
10.54%
2.79%
3.02%
1.44%
0.93%
0%
8.64%
11.20%
6.80%
2.49%
[17]
Assumption
[22]
[22]
[22]
[22]
[22]
Assumption
[22]
[22]
[22]
[22]
Screening Test (Tandem Mass Spectrometry)
- Sensitivity
- Specificity
99%
99.995%
[3]
[3]
Confirmation Test (Genetic Investigation)
- Sensitivity
- Specificity
- Cost
100%
100%
HKD $20,100
Assumption
Assumption
Hospital Authority
Treatment for Organic Acidemias
- Compliance to treatment 100% Assumption
Table 1: Summary of major estimates used for calculation of outcomes and costs in the decision tree pathways.
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No screening group
Disease outcome: In the no screening group, the expected numbers 
of OA outcomes is 2.31(out of 82,000). This was derived by incidence 
rate (0.0028%). From age-specific event probabilities, number of 
discounted life years lost is 7.40 while discounted number of life years 
with mental retardation development is 9.79.
Cost: Service utilization for the 5 OA cases identified in a local 
IEM study [17] was retrospectively retrieved. Utilization data 
including number of days of in-patient stays, number of out-patient 
consultation, and number of imaging service orders were retrieved. 
Average annual management cost per person based on NEP charges 
was HK$261,609. Using annual discount rate of 5%, the life time cost 
of the no screening group was expected to be HK$9,955,222.
Screening group
Disease outcome: From the incidence of OA, the expected number 
of OA cases is 2.31. Test sensitivity (true positive rate) further divide 
the cases into expected number of true positives (TP) category (n = 
2.29), and false negative (FN) category (n = 0.02). Likewise, from the 
specificity (true negative rate), the expected number of true negatives 
(TN) can be calculated (n = 82093.58), and the remaining cases 
belong to false positive (FP) cases (n = 4.10).
Assuming that all true positives (TP) cases are treated in time, 
i.e. no OA related death or mental retardation; and that all FN are 
incorrectly identified, the expected total number of life years lost is 
0.07 (discounted), and the expected number of life years with mental 
retardation is 0.10 (discounted) for screening group.
Cost: For TP cases, it is assumed that each case would have consultation 
quarterly. The life-time discounted management cost for each case is 
HK$86,547. For FN cases, the expected life-time management cost is 
the sum of the discounted cost of each life year up to their expected 
life years: HK$99,552.Costs for each group is calculated in Table 2, 
adding up to the group total of HK$426,000.
Incremental cost-effectiveness ratio: Incremental cost is then 
calculated to be -HK$9,529,223. Discounted benefits from screening 
were 7.33 life years saved, and 9.69 life years without mental 
retardation. Hence, the ICER per life year gained is -HK$1,300,177 
and the ICER per life year gained without mental retardation is 
-HK$983,333. As both figures fall below the cost-effectiveness 
threshold, population-wide TMS screening strategy is economically 
justified.
Discussion
Cost-effectiveness analysis
Inclusion of OA in newborn screening is found to be cost-
effective. This finding is comparable to other existing IEM cost-
effectiveness analysis. A Canadian study [23] also assessed the ICER 
per life year gain of expanding TMS-based newborn screening, from 
Phenylketonuria alone to 21 IEM diseases, including OA. In their 
study, the healthcare cost was also considered up to 80 of age, which 
is similar to our study. They also concluded that TMS is cost-effective 
when screening for a wider variety diseases. 
Most economic analyses for TMS-based screening strategy for 
OA also target other IEM diseases. The profile and choice of control 
group varies among studies. Schoen et al. [15] compared life-time 
treatment cost and outcomes for expanded TMS screening covering 
more than 5 IEM diseases (including two types of OA), with those of 
no screening, and estimated the cost per Quality-Adjusted Life Year 
(QALY) saved to be HK$45,451. (USD$5,827) Another study [14] 
considering life-time cost per QALY was estimated to be HK$90,168 
(USD$11,560) expanded TMS-based screening from 7 disorders to 
27 disorders. In Wisconsin, the cost per QALY was calculated as 
HK$118,966 (USD$15,252) for screening programme expanded from 
medium-chain acyl-coA dehydrogenase diseases alone to include OA 
and fatty acid oxidation disorders [24]. 
All ICERs calculated among studies reached their respective cost-
effectiveness thresholds. Although it is apparent that cost-effectiveness 
analysis from other localities may not be directly applicable to Hong 
Kong. Some variation is likely due to different evaluation approaches 
or a more contextualized environment.
Limitation of the study
This study was highly contextualized for practical purpose. It 
considered the occasion of additionally including OA screening to an 
existing TMS-based hyperphenylalaninemia screening platform. With 
low cost margin for screening procedure, costs difference between 
two groups mainly reflects the impact of early OA identification.
This study is heavily based on another local study [17], in 
which OA subjects were identified and followed-up. Subjects were 
all children, so their service utilization record was limited. Due to 
limited data on the management cost of OA, annual cost was averaged 
from 5-year period and was assumed to be uniform across the life 
time. Changes in annual management cost in OA subjects were not 
accounted for in this study. 
In the case of OA, the long-term cost of morbidity may even be 
higher. The Centers for Disease Control and Prevention in United 
States estimated the average lifetime cost for persons with mental 
retardation to be USD$1,014,000, at 3% discounted rate for future 
costs [25]. Among cost categories, direct medical costs only account 
for 13.8% of the total costs. Productivity loss to society contributes 
over 75% of the total life-time cost [25].There is inadequate data 
to calculate social and long-term care cost in Hong Kong. For the 
current model, from the public healthcare provider perspective and 
the length of study period, this large portion of unrealized societal 
cost is not considered.
Table 2: Cost involved in screening group (stratified).
OA subjects Healthy Subjects
Cost (HK$) True Positive
False 
Negative
True 
Negative
False 
Positive
Confirmation 20,100 / / 20,100
Management 86,547+ /* / /
Cost per case 106,647 /* / 20,100
Number of 
cases 2.29 /* 82,093.58 4.10
Total per group 
(HK$) 243,939
+ 99,552*+ 0 82,508
Subtotal: 426,000
+Discounted at 5% yearly discount rate. 
*Management cost for false negative group is separately calculated.
NB: Cost per case = cost of confirmation + cost of management
       Total cost per group = cost per case  × number of cases
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Another major challenge for researches of rare diseases is the lack 
of data. Ideally, estimates of disease costs, incidence, and outcomes 
would be derived from a single cohort by following them up 
throughout their lifetime. Nevertheless, such study is rarely feasible in 
practice. Most publications about rare diseases are presented as case 
reports, case series or observational studies, in which only descriptive 
figures recorded from observed subjects.  
For practical reasons, IEM studies often estimate incidence 
and disease outcomes by observation and projection. This may 
underestimate the incidence as cases are picked up mostly by 
clinical suspicion. Such strategy misses asymptomatic, mild, atypical 
or late-onset cases. As demonstrated by the experience of TMS-
based screening in Australia [26], the prevalence of IEM, excluding 
phenylketonuria, was adjusted from 8.6-9.5 per 100,000 births to 
15.7 per 100,000 upon implementation of screening. The effect of 
increased detection of asymptomatic or mild cases was not addressed 
in the study, but this is of significant importance to the screening 
programme. 
This study considers OA as a group of diseases. As OA is rare and 
longitudinal studies of OA patients are even rarer, the probabilities 
of outcomes were obtained based on a relatively small number of 
published observations. The diversity of clinical presentation and 
level of severity were yet to be addressed. The outcomes of OA were 
also simplified in the model, in which only two major adverse events 
were considered: mortality and development of mental retardation. 
Other outcomes, for example, seizure or acute symptoms were not 
considered. Therefore, the benefit from screening may have been 
underestimated in this model. 
There is also ambiguity about effectiveness of treatment. Although 
it has been known that OA subjects have good response to treatment 
[6], details and statistics on treatment efficacy are yet to be published. 
The period of onset during which treatment improve outcome has yet 
to be studied, hence was not incorporated in the model.
Future studies
This study is, to the understanding of the authors, the first 
economic evaluation of TMS-based platform for newborn OA 
screening. This study has solely considered OA. In future studies, 
cost-effectiveness can be calculated for more than one disease 
group; and incorporate existing G6PD deficiency and congenital 
hypothyroidism screening programmes in Hong Kong.
Cipriano, et al [23] performed a cost-effectiveness analysis 
on TMS-based newborn screening for up to 21 IEM diseases. By 
step-wise addition of diseases to the existing screening program, 
they calculated the ICER and determined the optimal condition in 
which the greatest number of diseases that could be identified. It is 
believed that this study is potential to be a pilot model for a bigger 
project to have a better picture of overall cost-effectiveness of TMS-
based screening strategy; and to establish the optimal framework of 
newborn IEM screening in Hong Kong.
Conclusion
Cost-effectiveness of newborn screening for OA was analysed 
using a decision tree with a 5-year cohort. With screening, ICER per 
life year gained and per life year gained without mental retardation 
are -HK$1,300,177 and -HK$983,333 respectively compared with 
no screening strategy, which are both less than GDP per capita. 
Population-wide screening is shown to be highly economically 
favourable to avoid mortality and mental retardation from a public 
healthcare provider’s perspective.
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